A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Incyte Corporation
Study ID
NCT06505265
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered povorcitinib.in healthy participants.

Key Dates

Start date
Aug 12, 2024
Status verified
Sep 2024
Primary completion
Sep 18, 2024
Completion
Sep 18, 2024

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Povorcitinib
    Povorcitinib will be administered at the protocol defined dose.

Primary Outcome Measure

Pharmacokinetic (PK) in dermal povorcitinib [ Time Frame: Up to Day 17 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion, IncLincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion, Inc· Lincoln, NE

Related Studies